104 results on '"Bagg, Adam"'
Search Results
2. Performance Evaluation of a Novel Artificial Intelligence–Assisted Digital Microscopy System for the Routine Analysis of Bone Marrow Aspirates
3. TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era
4. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
5. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study
6. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
7. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group
8. Transcriptome and unique cytokine microenvironment of Castleman disease
9. Myeloid/lymphoid neoplasms with FLT3 rearrangement
10. Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML
11. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group
12. Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice
13. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1
14. Chapter 5 - Molecular Pathology of Hematologic Neoplasms
15. Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion
16. Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group
17. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
18. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study
19. Genetic studies in the evaluation of myeloproliferative neoplasms
20. A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria
21. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
22. Myeloproliferative neoplasms with concurrent BCR–ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group
23. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia
24. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
25. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified
26. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
27. Contributors
28. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
29. The Genetic Basis and Expanding Role of Molecular Analysis in the Diagnosis, Prognosis, and Therapeutic Design for Myelodysplastic Syndromes
30. Microsphere-Based Multiplex Analysis of DNA Methylation in Acute Myeloid Leukemia
31. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
32. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
33. Genomic profiling for clinical decision making in lymphoid neoplasms
34. Acute Myeloid Leukemia: Conventional Cytogenetics, FISH, and Moleculocentric Methodologies
35. Transitioning T-Cell Clonality Testing to High-Throughput Sequencing
36. IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue
37. Malleable Immunoglobulin Genes and Hematopathology – The Good, the Bad, and the Ugly: A Paper from the 2007 William Beaumont Hospital Symposium on Molecular Pathology
38. Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms
39. Optimizing the Integration of Genetic Testing in AML Care in Community Practice: Insights from a Quality Improvement Initiative
40. TP53 Mutations Detected By Clinical Laboratory Mutation Analysis Predict for Inferior Clinical Outcomes in Patients with Newly-Diagnosed Aggressive B Cell Lymphomas, Including Those with High-Risk Features
41. Impact of Genetic Mutations on Survival Following Receipt of Commercial CART19 for Patients Diagnosed with Aggressive B Cell Lymphoma
42. Guidance for Fluorescence in Situ Hybridization Testing in Hematologic Disorders
43. A novel t(3;8)(q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma
44. VEXAS’d by lymphadenopathy: an unusual case of extramedullary hematopoiesis
45. High-throughput sequencing of the T-cell receptor β chain gene distinguishes 2 subgroups of cutaneous T-cell lymphoma
46. CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10 + T cells by flow cytometry
47. Expedited Analysis and Reporting of Multiple Mutations that Modify Medical Management of Myeloid Malignancies: It's About (Turnaround) Time!
48. Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines
49. Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease
50. Next-Generation Sequencing for Lymphomas: Perfecting a Pipeline for Personalized Pathobiologic and Prognostic Predictions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.